The head of Zealand Pharma has called its $5.3bn partnership with Roche to commercialise an obesity drug with fewer ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning ...

Last month, Roche reached a $1.65 billion deal to partner in the development of a Zealand Pharma obesity drug that goes after a different target than the currently available weight management ...

Zealand Pharma begins patient enrolment in phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes: Copenhagen, Denmark Saturday, April 2 ...

With the threat of pharmaceutical tariffs hanging over the biopharmaceutical industry, Roche is the latest addition to a ...

COPENHAGEN, April 24 (Reuters) - Danish biotechnology company Zealand Pharma (ZELA.CO), opens new ... on late-stage trials and sales development, Roche said at the time. The two companies will ...

Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech ...

Swiss pharmaceutical giant Roche on Tuesday said that it would invest $50 billion in the U.S. over the next five years, amid ...

Roche posted higher-than-expected first-quarter sales, driven by robust demand for its key drugs, as the company takes active steps to preempt looming U.S. import tariffs. To strengthen its U.S ...

Roche CEO Thomas Schinecker said in a statement on Tuesday that the company’s new $50 billion investment demonstrated its ...

Roche projected that its $50 billion manufacturing investment, to include R&D operations, will generate 1,000 jobs at the ...

Enrollment and randomization in ZUPREME-1 was completed in three months. In March 2025, Zealand Pharma and Roche entered a collaboration and license agreement to co-develop and co-commercialize ...